Compare Apartment Investment and Management Co (AIV) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apartment Investment and Management Co vs Neurocrine Biosciences Inc — how do they compare? Apartment Investment and Management Co trades at $2.9 (market cap $422.94M), while Neurocrine Biosciences Inc trades at $176.74 (market cap $17.84B). The key difference: Neurocrine Biosciences Inc is far larger — about 42.2× Apartment Investment and Management Co's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.
| AIV | NBIX | |
|---|---|---|
Market Cap | $422.94M | $17.84B |
Sector | Real Estate | Health |
52-Week High | $8.76 | $177.49 |
52-Week Low | $2.87 | $123.10 |
Enterprise Value | $669.06M | $16.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.94, down 0.68% on the day, with a bearish technical signal from moving averages. The company reported a net income of $554.01M for 2025, driven by a significant tax benefit, though revenue declined to $138.49M. Analyst consensus is mixed with 1 Buy and 2 Hold ratings. A $1.30 per share liquidating distribution is scheduled for June 2026, reflecting corporate restructuring efforts.
Outlook is cautious due to volatile earnings history and declining revenue, but the high net income margin and planned distribution offer some investor appeal. Key risks include inconsistent operational performance and high leverage, while institutional sentiment remains neutral pending clearer growth catalysts.
Neurocrine Biosciences (NBIX) trades at $174.1, showing modest daily movement with a slight decline of 0.09%. The stock exhibits strong bullish technical signals from moving averages and a consensus analyst buy rating of 86.49%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.94 surpassing the $1.22 estimate. Revenue growth is robust, climbing from $2.86B in 2025 to a projected $3.1B in 2026, supported by blockbuster products Ingrezza and Crenessity.
NBIX presents a favorable outlook with upward earnings momentum and strategic acquisitions strengthening its neuroscience portfolio. Key risks include pipeline execution challenges and competitive pressures. The consensus price target of $192.91 suggests approximately 11% upside potential from current levels, making it an attractive growth stock despite elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
